Takeshi Suzuki

发表

Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study

K. Chìn, D. Takahari, H. Osumi, 2020, BMC Cancer.

Clinical utility of PEG-G-CSF for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: A single centor retrospective study

K. Chìn, D. Takahari, H. Osumi, 2019 .

Non‐V600E BRAF mutations and EGFR signaling pathway in colorectal cancer

Y. Miki, K. Chìn, D. Takahari, 2019, International journal of cancer.

Serum squamous cell carcinoma antigen is a predictive factor of outcomes in patients with locally advanced unresectable esophageal squamous cell carcinoma treated by definitive chemoradiotherapy

K. Chìn, Masayuki Watanabe, D. Takahari, 2022, Journal of Cancer Metastasis and Treatment.

Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake

K. Chìn, D. Takahari, H. Osumi, 2018, OncoTargets and therapy.

Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study

K. Chìn, D. Takahari, H. Osumi, 2019, Cancer management and research.

Safety and ef fi cacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract : a single cancer center retrospective study

K. Chìn, D. Takahari, T. Ichimura, 2019 .

Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study

K. Chìn, D. Takahari, H. Osumi, 2020, BMC Cancer.

Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan

E. Baba, N. Sugimoto, Yoshiyuki Yamamoto, 2022, Gastric Cancer.

Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma

Masayuki Watanabe, D. Takahari, H. Osumi, 2019, Annals of Surgical Oncology.

Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting

D. Takahari, H. Osumi, K. Yamaguchi, 2020, ESMO Open.

Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival

D. Takahari, H. Osumi, T. Ichimura, 2020, Cancer Chemotherapy and Pharmacology.

Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer

D. Takahari, H. Osumi, T. Ichimura, 2019, Cancer Chemotherapy and Pharmacology.

Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer

D. Takahari, H. Osumi, T. Ichimura, 2018, Cancer management and research.

Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research

D. Takahari, H. Osumi, K. Yamaguchi, 2020, International Journal of Clinical Oncology.

ASO Author Reflections: How Should We Approach Borderline Resectable Esophageal Squamous Cell Carcinoma?

Masayuki Watanabe, A. Okamura, Takeshi Suzuki, 2020, Annals of Surgical Oncology.